La cadena de opciones muestra datos clave de las opciones de acciones de Sonnet BioTherapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Sonnet BioTherapeutics..

Sonnet BioTherapeutics (NASDAQ:SONN) Bolsa, Cadena de Opciones

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics Holdings Inc

News

NKTR

Nektar Therapeutics Announces Completion Of Target Enrollment In REZOLVE-AA Phase 2b Clinical Trial Of Rezpegaldesleukin In Patients With Severe-to-Very Severe Alopecia Areata

On February 20, 2025, the Company's Board of Directors increased by one cent the Company's regular quarterly dividend effective from the first quarter of 2025 and declared a $0.07 per share dividend for the first quarter of 2025. The cash dividend is payable on March 27, 2025 to all stockholders of record of Class A and Class B common stock as of the close of business on March 19, 2025.

Dividends

Bentley Systems Board Approves One-Cent Dividend Increase for Q1 2025 To $0.07/Share

Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) reported quarterly losses of $(2.71) per share which beat the analyst consensus estimate of $(4.16) by 34.86 percent. This is a 52.29 percent increase over losses of $(5.68) per share from the same period last year. The company reported quarterly sales of $103.22 million which beat the analyst consensus estimate of $98.56 million by 4.73 percent.

Earnings

Earnings Beats

MDGL

Madrigal Pharmaceuticals Q4 2024 GAAP EPS $(2.71) Beats $(4.16) Estimate, Sales $103.22M Beat $98.56M Estimate. Cash And Equivalents Of $931.3M

COCO

Vita Coco Company Sees 2025 Net Sales To Be Between $555M-$570M Vs. $569.11M Estimate

Barclays analyst Raimo Lenschow maintains ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) with a Equal-Weight and raises the price target from $11 to $13.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on ZoomInfo Technologies, Raises Price Target to $13

Buybacks

Dycom Board Authorizes New $150M Stock Repurchase Program

Avista (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVA#NYSE">AVA</a>) reported quarterly earnings of $0.84 per share which missed the analyst consensus estimate of $0.89 by 5.62 percent. This is a 22.22 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $517.00 million which beat the analyst consensus estimate of $480.62 million by 7.57 percent. This is a 2.49 percent increase over sales of $504.44 million the same period last year.

Earnings Misses

Avista Q4 2024 GAAP EPS $0.84 Misses $0.89 Estimate, Sales $517.00M Beat $480.62M Estimate

Sprott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SII#NYSE">SII</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.48 by 4.17 percent. This is a 21.05 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $36.80 million which missed the analyst consensus estimate of $38.30 million by 3.89 percent. This is a 1.84 percent increase over sales of $36.14 million the same period last year.

Sprott Q4 EPS $0.46 Misses $0.48 Estimate, Sales $36.80M Miss $38.30M Estimate

Biotech

General

CGTX

Cognition Therapeutics Says Masked Analysis Showed Participants Receiving Oral Zervimesine For At Least Least 6 Months Experienced Slower Lesion Growth Than Participants Receiving Placebo

Editor&#8217;s Note: This story has been updated with additional information.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) researcher Troy Teslike on Wednesday said that the EV company will likely not deliver 500,000 vehicles in a quarter in 2025 either, mostly owing to &#8220;brand sentiment issues.&#8221;
What Happened: The highest deliveries by Tesla in a quarter to date was in the fourth quarter of 2024 when the company delivered 495,570 vehicles. The company was aiming for over 500,00 deliveries but fell short because of demand issues. 
&#8220;Sadly reaching 500,000 in a single quarter doesn't seem possible this year either, mostly because of brand sentiment issues,&#8221; Teslike said in a post on social media platform X. 
&#8220;This year's best quarter will likely be below 470,000 units but the situation seems to be getting worse, and soon even 450,000 might be hard to achieve,&#8221; Teslike said. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla delivered 495,570 cars in Q4 2024. They came very close to 500,000 but didn't quite make it because of demand issues. Sadly, reaching 500,000 in a single quarter doesn't seem possible this year either, mostly because of brand sentiment issues. This year's best quarter will… <a href="https://t.co/HjT0kyzwe2">pic.twitter.com/HjT0kyzwe2</a>
&mdash; Troy Teslike (@TroyTeslike) <a href="https://twitter.com/TroyTeslike/status/1894654134730530882?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The sentiment around Tesla is deteriorating owing to Elon Musk&#8217;s association with President Donald Trump and his support for far-right leaders and parties such as Alternative for Germany. The Department of Government Efficiency, led by Musk and aimed at slashing federal government spending, is also firing or forcing out government workers across departments, giving rise to protests.
Why It Matters: Tesla reported a fall in vehicle deliveries for the first time in over a decade in 2024. Tesla reported global&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on" target="_blank" rel="noreferrer noopener">deliveries of 1.79 million</a>&nbsp;vehicles, down from full-year deliveries of 1.81 million in 2023.
In the democratic state of California, Tesla had only 203,221 vehicle registrations in 2024, nearly 12% lower than the year before, according to data from the California New Car Dealers Association (CNCDA).
Deliveries are not faring well since the start of this year either.
According to data from the China Passenger Car Association, <a href="https://www.benzinga.com/tech/25/02/43556649/tesla-drops-1-5-premarket-after-sales-of-china-made-evs-in-january-drop-11-5-yoy">Tesla&#8217;s China-made EV sales fell 11.5% to 63,238 units in January</a>. Of these 29,535 were exported to outside China.
In the European Union, Tesla&#8217;s new car registration<a href="https://www.benzinga.com/25/02/43934934/new-tesla-registrations-dip-by-50-in-eu-in-january-despite-rising-overall-bev-market-share"> fell by over 50%</a> in January despite a rise in overall battery electric vehicle registrations, according to data from the European Automobile Manufacturers Association (ACEA).
Tesla CEO Elon Musk said in October that he expects a 20-30% increase in deliveries in 2025. However, the CEO didn't reiterate the target during the company's fourth-quarter earnings in January. Instead, Tesla only said that it expects the vehicle business to "return to growth" in 2025, possibly implying that deliveries would be higher than in 2024.
Tesla did not immediately respond to Benzinga&#8217;s request for comment.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43966461/lucid-to-up-production-increase-advertising-and-sell-in-saudi-arabia-to-up-high-end-gravity-suv-sales-this-year">Lucid Gravity Customers Opting For High-End Configurations, All The Way Up To $120,000: CEO Says SUV &#8216;Attracting New People To The Brand&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Unlikely To Deliver 500,000 EVs In A Quarter In 2025, Says Researcher: 'Doesn't Seem Possible This Year Either' (UPDATED)

Photronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAB#NASDAQ">PLAB</a>) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.47 by 10.64 percent. This is a 8.33 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $212.14 million which beat the analyst consensus estimate of $210.00 million by 1.02 percent. This is a 1.94 percent decrease over sales of $216.33 million the same period last year.

PLAB

Photronics Q1 2025 Adj EPS $0.52 Beats $0.47 Estimate, Sales $212.14M Beat $210.00M Estimate

Guidance

AVNS

Avanos Medical Sees 2025 Net Sales To Be Between $665M-$685M Vs. $713.13M Estimate, And Adjusted Diluted Earnings Per Share Are Expected To Be Between $1.05-$1.25 Vs. $1.67 Estimate

SkyWater Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.06) by 166.67 percent. This is a 300 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $75.49 million which beat the analyst consensus estimate of $74.18 million by 1.76 percent. This is a 4.63 percent decrease over sales of $79.15 million the same period last year.

SKYT

SkyWater Technology Q4 2024 Adj EPS $0.04 Beats $(0.06) Estimate, Sales $75.49M Beat $74.18M Estimate

For the full year 2025, the Company expects net sales to be in the range of $158 million to $163 million, and an adjusted EBITDA loss in the range of $8 million to $11 million. Adjusted EBITDA guidance reflects a planned increase in marketing and promotional spend as the Company reinvests cost savings into future growth.
For the first quarter of 2025, the Company expects net sales to be in the range of $36 million to $38 million, and an adjusted EBITDA loss of between $5.6 million and $6.0 million. The net sales guidance reflects the impacts of the aforementioned lost distribution in our club channel and one customer in our mass channel. Adjusted EBITDA reflects planned reinvestment in marketing spend, particularly in the first and third quarters of 2025.

ZVIA

Zevia Expects Q1 Revenue Of $36M-$38M Vs $42.36M Est, FY25 Revenue Of $158M-$163M Vs $167.24M Est

Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) reported quarterly losses of $(0.72) per share which met the analyst consensus estimate. This is a 2.86 percent decrease over losses of $(0.70) per share from the same period last year. The company reported quarterly sales of $41.83 million which beat the analyst consensus estimate of $38.48 million by 8.69 percent. This is a 72.61 percent increase over sales of $24.23 million the same period last year.

RYTM

Rhythm Pharmaceuticals Q4 EPS $(0.72), Inline, Sales $41.83M Beat $38.48M Estimate

Barclays analyst Ryan Macwilliams maintains Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Equal-Weight and lowers the price target from $85 to $80.

Barclays Maintains Equal-Weight on Zoom Communications, Lowers Price Target to $80

Needham analyst Mayank Tandon reiterates PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from Hold to Hold.

Reiteration

PYPL

Needham Reiterates Hold on PayPal Holdingsto Hold

Barclays analyst Jiong Shao maintains Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) with a Overweight and raises the price target from $131 to $148.

Barclays Maintains Overweight on Sea, Raises Price Target to $148

Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) reported quarterly earnings of $1.17 per share which beat the analyst consensus estimate of $0.90 by 30 percent. This is a 48.1 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $1.08 billion which beat the analyst consensus estimate of $1.03 billion by 5.60 percent. This is a 13.81 percent increase over sales of $952.46 million the same period last year.

Dycom Industries Q4 2025 Adj EPS $1.17 Beats $0.90 Estimate, Sales $1.08B Beat $1.03B Estimate

This approval triggers a $5 million milestone payment to Ardelyx under the terms of the license agreement between Ardelyx and its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma). Under the terms of its agreement,&nbsp;Ardelyx is eligible to receive additional developmental and commercialization milestones of up to&nbsp;$100 million&nbsp;and tiered royalty payments on net sales ranging from the mid-teens to 20 percent.

ARDX

Ardelyx's Tenapanor Approved In China For Hyperphosphatemia, Triggering $5M Milestone Payment

Press Releases

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Management

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Health Care

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Comments

Sonnet BioTherapeutics

Sonnet BioTherapeutics (SONN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL